Table 4.
Clinical trials of promising candidates for drug repositioning against COVID-19 (SARS-CoV-2)
| ID | Population | Drug | Indication | Phase |
|---|---|---|---|---|
| NCT04292899 | 400 | Remdesivir | Antiviral (Ebola and Marburg) | III |
| NCT04273529 | 100 | Thalidomide | Immunomodulatory agent, antiangiogenic, TNF blocking agent. | II |
| NCT04308317 | 60 | Tetrandrine | Anti-inflammatory, immunologic and antiallergenic | IV |
| NCT04318015 | 400 | Hydroxychloroquine | Antimalarial and anti-inflammatory (Rheumatoid arthritis and lupus) | III |
| NCT04316377 | 202 | Chloroquine | Antimalarial and anti-inflammatory (Rheumatoid arthritis and lupus) | IV |
| NCT04260594 | 380 | Umifenovir (Arbidol) | Antiviral (influenza) | IV |
| NCT04286503 | 520 | Carrimycin | Antibiotic (macrolide) | IV |
| NCT04303299 | 80 | Oseltamivir | Antiviral (influenza) | III |
| NCT04303299 | 80 | Favipiravir | Antiviral (influenza) | III |
| NCT04311177 | 516 | Losartan | Antihypertensive | II |
| NCT04275414 | 20 | Bevacizumab | Antitumoral (anti-VEGF) | II |
| NCT04311697 | 20 | Aviptadil | Erectile dysfunction treatment | II |
| NCT04305457 | 240 | Nitric oxide Gas | Pulmonary hypertension treatment | II |
| NCT04320277 | 60 | Baricitinib | Anti-inflammatory (rheumatoid arthritis) | III |
| NCT04291729 | 11 | Danoprevir | Antiviral (hepatitis C) | IV |
| NCT04286503 | 520 | Ritonavir | Antiretroviral | IV |
| NCT04288713 | - | Eculizumab | Hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria treatment | - |
| NCT04317092 | 330 | Tocilizumab | Rheumatoid arthritis treatment | II |
| NCT04286503 | 520 | Lopinavir | Antiretroviral | IV |
| NCT04276688 | 70 | Ribavirin | Antiviral (hepatitis C) | II |
| NCT04315298 | 400 | Sarilumab | Rheumatoid arthritis treatment | II |
All data were obtained from a manual search in clinicaltrial.gov